Cannabis Science Product Line To Feature Proprietary Medical Formulations For Chronic Pain, Fibromyalgia

Cannabis Science Product Line To Feature Proprietary Medical Formulations For Chronic Pain, Fibromyalgia

Colorado Springs, Colorado based Cannabis Science, Inc., a company specializing in cannabis-based drug development and related consulting work, has announced readiness to release its first line of European medicinal cannabis products at Spannabis 2015, to be held at Barcelona, Spain, from March 20th — 22nd. These medicines will incorporate Cannabis Science proprietary formulations developed in Spain and the Netherlands. The company’s product pipeline addresses a wide range of diseases and symptoms, including Chronic Pain and Fibromyalgia.


Spannabis, the world’s largest Cannabis conference, has been held in Barcelona since 2004. At last year’s conference, 500 companies were represented, and 33.000 visitors attended from Belgium, Canada, China, France , Germany, Hungary, Ireland, Italy, Poland, Russia. Slovenia, Spain, Switzerland, The Netherlands, United Kingdom, and the USA.


The 2015 meetings will be Cannabis Science’s first time exhibiting at the internationally acclaimed conference. “We are delighted to be attending Spannabis and showcasing our products that have been in drug development pipeline for the last two years, after rigorous testing we are excited to show them to Spain and the rest of the world,” the company notes in a release. Cannabis Science, Inc. launched its toll-free call center in preparation for multiple global product launches that took place on March 3.

Company CEO, President & Co-Founder Raymond C. Dabney also recently shared his thoughts on the burgeoning medical cannabis industry with Chicago HR Examiner columnist Pam C. Waits, discussing the company’s goals and directional focus, and relating how Cannabis Science is helping build awareness of medical cannabis products’ effectiveness, and how it is working toward bringing cannabinoid-based medicines to the forefront of healthcare practice through credible scientific research and development.

Reporter Ms. Waits, who has been writing for Chicago Examiner since 2011, commented that “The reader response to my Q&A with Raymond has been overwhelming. His focus and serious approach for leading a company without an industry blueprint is impressive and insightful.”You can read the Q&A in its entirety, here:

“We have been overwhelmed with phone calls and emails in regards to our pre-clinical studies, state-by-state initiatives, new product releases, cannabinoid treatment education, and project partnerships,” says Mr. Dabney in a release. “This shows the general public interest and momentum toward understanding the use of cannabinoids. It is very difficult to reach out to everyone while progressing our drug development programs to meet the critical growing demand. We are very excited to report that all is moving much stronger and faster than we could have anticipated.”

Mr. Dabney says: the Cannabis Science Research Foundation’s new call center will provide opportunity public and healthcare professionals to find out more about the company’s goals, the sterling credentials of CBIS scientific and medical leaders, current and future pre-clinical studies being conducted and planned and upcoming product launches in both the U.S. and abroad as the Foundation’s “state by state initiatives” grow along with rapidly changing medical marijuana laws and increasingly favorable public perception.

“California has given us some exciting new developments as we await our final product approvals and manufacturing,” Mr. Dabney notes. “Our aggressive schedule has lead to exciting events we believe will greatly benefit those of interest, as our final product launch date is approaching rapidly. I believe this will be well worth the wait.”

He further notes that “Michigan has now matured to the point of multiplied returns,” and he believes it “will be another very important state for the company and the general public.” He reports that the Foundation’s New York initiatives are also “slowly coming to a head” as required teams are being developed to handle what will be a huge market there. Mr. Dabney also cites “some very special relationships in Washington DC,” noting that his frequent travel there “has been a serious eye opener and has given us the ability to move in a circle of influence as never before,” and that several other state targets are no less important from a drug development and delivery standpoint, with the company constantly sorting through new opportunities to advance its programs and to deliver at an accelerated rate. He says they look forward to hearing from the public, investors and the medical community via the new call center.

Prior to the mid-20th Century, cannabinoids had been a valued component of the medical pharmacopeia, with a therapeutic history dating back thousands of years. There is a vast body of peer-reviewed scientific literature documenting the underlying biochemical pathways that cannabinoids modulate — an endocannabinoid system inherent to all vertebrates regulates all body systems and helps maintain homeostasis, and with mechanisms of phytocannabinoids biological impact consequently multidimensional.

Hundreds of natural constituents covering several chemical classes have been isolated and identified from the Cannabis plant.

Cannabinoids belong to the chemical class of terpenophenolics, of which 85 have been uniquely identified in cannabis, including the famously, or infamously depending on point of view, most psychoactive cannabinoid tetrahydrocannabinol or THC.

Some other key medically active phytocannabinoids include:

  • cannabidiol (CBD)
  • cannabigerol (CBG)
  • cannabichromene (CBC)
  • cannabinol (CBN)

Cannabis Science notes that some medical cannabinoid applications have been well established in peer-reviewed literature such as for alleviation of nausea and stimulating the appetite for people with AIDS and cancer. Other well-known therapeutic applications include easing chronic pain and reducing muscle spasms associated with neuromuscular disorders like MS and spinal cord injuries. Other current uses are less-well understood, such as cannabinoids’ perceived effectiveness in alleviating certain autoimmune disorders, such as Crohn’s Disease.

Cannabis Science’s development team is working to produce and commercialize products derived from cannabis-based botanical extracts, the company noting that even today, new medicinal uses for cannabinoids are being discovered. For example, recent discovery that topical cannabinoid-based preparations can be effective against Methicillin-resistant Staphylococcus aureus (MRSA) infections caused by a strain of staph bacteria that’s developed resistance to antibiotics commonly used in hospitals. Other topical applications, (which are largely non-psychoactive) could target localized pain, such as arthritis and burns, as well as neuropathic pain, for which there are few effective treatments.

Cannabis Science, Inc. observes that with ever-increasing use and scientific support for cannabinoid medicines occurring in the US and around the world, they are anticipating growth of a new multi-billion dollar industry that will have a dramatically positive impact on human health globally, with the company well-poised to take advantage of its unique understanding of metabolic processes and to provide innovative treatment options for unmet medical needs.

The company says it is dedicated to working closely with local, national and international regulatory agencies to provide access to high quality, first class cannabinoid pharmaceuticals to persons critically in need of effective, safe treatments for life threatening and debilitating conditions. Cannabis Science’s clinical trial material comes from cGMP compliant cultivation and production facilities that exceed high quality standard industrial and food processing requirements, and the company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for treatment of multiple critical ailments from cancer and infections to age-related illnesses and neurobehavioral disorders.

The company’s products, broadly described, are medical cannabinoid formulations developed from one or more of the cannabinoid compounds found in the cannabis plant. The most immediate development immediate focus is on finding cutting edge cancer treatments. Future endeavors are to include infectious illnesses, neurobehavioral disorders including attention deficit disorder, post-traumatic stress disorder; and an application of the anti-inflammatory activities of cannabis in the management of age-related illnesses, proving innovative therapeutics for unmet medical needs.

In 2013, Cannabis Science also submitted patent application N2010968 in Europe entitled “Composition for the Treatment of Neurobehavioral Disorders” (CS-NEURO-1). The subject of the patent is development of cannabinoid-based formulations to treat a variety of neurobehavioral disorders.

Proprietary formulations that have been undergoing development in Spain and the Netherlands include:

Mid-Tier Critical Ailment Application Usage (new formulations)

1. CS-M4 (Ingested and Topical formulations)

Applications: side effects chemo therapy, chronic pain, muscle problems, sleeping disorders, nausea, ADHD, Rheumatism, arthritis, infections, diabetes, manic depression and fibromyalgia.

2. CS-M18 (Ingested and Topical formulations)

Applications: side effects chemo therapy, chronic pain, muscle problems, sleeping disorders, nausea, ADHD, Rheumatism, arthritis, infections, diabetes, manic depression and fibromyalgia.

3. CS-ACCV (Topical Formulations)

Applications: rheumatism, fibromyalgia, arthritis, eczema, sporting injuries, radiotherapy wounds, muscle and neck pain.

4. CS-CLDL (Topical Formulations) whole plant based cannabinoid formulation

Applications: radiotherapy wounds, rheumatism, open wounds, sensitive and irritated skin.

5. CS-CRRT (Topical Formulations) whole plant based cannabinoid formulation

Applications: various skin complaints, wounds and eczema.

“This will be the first time Cannabis Science has publicly showcased products to a European audience. We are pushing to get the product line into the hands of people needing it most,” says Mr. Dabney.

Catalonia (of which Barcelona is capital) has recently passed laws to introduce medical cannabis clubs in Spain under Spanish law. Cannabis Science says it intends on leveraging its experience in regulatory frameworks to establish and be a driving force in the cultivation, research and development around extraction and helping the introduced regulatory measures co-exist within a developing larger European market.

Cannabis Science is currently harvesting 40 acres of cultivation facilities in Spain and is working aggressively to partner with patient organizations, public healthcare systems and private companies to expand its on-going commitments in the emerging market.

Raymond Dabney says Cannabis Science Inc. believes that “the correct way is to look at the industry from a bio-pharmaceutical standpoint, in a manner that allows cannabinoid-based products to modulate the endocannabinoid system to treat multiple conditions. Scientifically, we know this is the beginning of one of the greatest expansions of medicine and industry we will ever experience in our lifetime.”

He notes that a recent focus of the company’s new Drug Development Initiatives has been continuing to develop a world-class research team and operational structures capable of meeting a growing global demand while launching pre-clinical studies in Europe, pre-clinical initiatives in the United States and other global initiatives. The company has also initiated an African healthcare initiatives program targeting key issues and international concerns. As the newly appointed Vice Chair of the recently launched Constituency for Africa (CFA) Africa Healthcare Infrastructure Committee, Mr. Dabney joins retired U.S. Assistant Surgeon General Dr. Roscoe M. Moore Jr., who is CFA Interim Chair and Chair of the Africa Healthcare Infrastructure Committee.

“We are looking forward to announcing some more exciting groundbreaking news as we progress through these international landscapes favorably,” Mr. Dabney affirms, noting that “Scholars, economists, industrialist and high-ranking government officials worldwide are all well aware of how important the redevelopment of this Continent is right now. We have a special interest in strengthening the healthcare infrastructure to assist in the reconstruction of such an important continent. Again, I am greatly honored to be brought in so close among such great leaders, to help make a difference in Africa right now. We are rapidly determining how the Cannabis Science team can help make an immediate and long-term difference.”

Cannabis Science, Inc. invites the public and healthcare professionals to call 1.888.889.0888 toll-free to speak with its team to learn more about the company and its focus to develop groundbreaking cannabinoid-based treatments.

Cannabis Science, Inc.
Chicago HR Examiner
Spannabis 2015

Image Credit:
Spannabis 2015